1644.0000 -12.00 (-0.72%)
NSE Sep 22, 2025 15:31 PM
Volume: 1.8M
 

1644.00
-0.72%
Dolat Capital
Given the structural headwinds in the US faced by Indian generic companies, Sun's investments to build a branded specialty business is a key differentiator. However, Specialty pharma is a vastly different business model compared to traditional generics requiring significantly...
Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended